Approximately 74,000 cases of Non-Hodgkin’s lymphoma (NHL) are reported each year.
NHL is a form of cancer that originates in the lymph nodes, like Hodgkin’s lymphoma, yet it is a completely separate disease.
There are many different categories of NHL, defined by how aggressive the disease behaves. The disease ranges from low-grade NHL, in which case some patients are closely monitored for four to five years before needing treatment, to high-grade NHL, in which case patients need to be treated as soon as possible.
The most common symptom of Non-Hodgkin’s lymphoma is painless, swollen lymph glands that continue to increase in size, often occurring under the neck or under the arm; however, NHL can occur in any of the hundreds of lymph nodes within the body. Other, less common symptoms include weight loss, fever and night sweats.
Fortunately, Non-Hodgkin’s lymphoma is a treatable, and very often, curable disease. Proper chemotherapy protocols combined with a targeted therapy known as Rituximab, that has revolutionized treatment for NHL, significantly increased survival rates.
Research efforts continue to focus on understanding the genetic abnormalities of each patient’s lymphoma, and developing individualized treatment programs for each patient. The team of medical experts at Cone Health Cancer Center, and its satellite centers at Annie Penn Hospital and MedCenter High Point, are dedicated to providing exceptional care for individuals in the community with different forms of lymphoma. The Cancer Center is also actively involved in clinical trials studying advancements in the treatment of various forms of cancer.
Dr. Peter Ennever is an oncology and hematology specialist at Cancer Center at MedCenter High Point, an accredited satellite of the Cone Health Cancer Center. Dr. Ennever is a 1988 medical school graduate of George Washington University. He completed his residency at University of Pittsburgh Health Science Center and completed a fellowship in Hematology and Medical Oncology at Yale-New Haven Hospital.